A study on rhabdomyosarcoma showed that reduced ANT1 expression could affect mitochondrial function and was involved in tumor cell metabolism and death pathways, leading to tumorigenesis, which indicated that ANT1 might be a therapeutic target for rhabdomyosarcoma. The gene discussed is SLC25A4; the disease is rhabdomyosarcoma.